表紙
市場調査レポート

Engerix-B(B型肝炎ウイルス(HBV)予防ワクチン)- 予測と市場分析

Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 298839
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
Engerix-B(B型肝炎ウイルス(HBV)予防ワクチン)- 予測と市場分析 Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
出版日: 2014年01月31日 ページ情報: 英文 67 Pages
概要

B型肝炎は、B型肝炎ウイルス(HBV)によって引き起こされる、急性または慢性の肝炎です。世界におけるHBVの感染者数は約20億人で、HBV関連の肝疾患で毎年約60万人が亡くなっています。遺伝子組換えHBV表面抗原(HBsAg)ワクチンによって、過去20年間で、病気の負担は大きく軽減しましたが、成人におけるワクチン摂取と有効性への疑問は依然として残っています。

当レポートでは、GSKによる単価ワクチンEngerix-Bについて調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 概要
  • 病因・病態生理
  • 症状
  • 予後

第4章 ワクチン接種勧告と接種率

  • 概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 Engerix-B

  • 概要
  • 免疫原性
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC334DFR

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Engerix-B [Hepatitis B Vaccine (Recombinant)] is GSK's monovalent vaccine that protects children, adolescents, and adults against acute and chronic infections caused by all known strains of HBV. Following the 1986 debut of Merck's hepatitis B offering, Recombivax HB, Engerix-B was the second recombinant HBV vaccine to receive FDA approval. Engerix-B also received market authorization in Canada in 1991 and the 5EU in 2000. It is marketed under the names Engerix-B Kinder/Engerix-B Erwachsene in Germany.

Scope

  • Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Engerix-B including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Engerix-B for top seven countries from 2012 to 2022.
  • Sales information covered for the US, Canada, France, Germany, Italy, Spain and the UK

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Engerix-B performance
  • Obtain sales forecast for Engerix-B from 2012-2022 in the top seven countries (the US, Canada, France, Germany, Italy, Spain and the UK).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Engerix-B

  • 6.1. Overview
  • 6.2. Immunogenicity
  • 6.3. Safety
  • 6.4 SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Patient Populations Targeted for Vaccination
    • 7.4.2. Vaccination Coverage Rates
    • 7.4.3. Vaccinated Patients
    • 7.4.4. Regulatory Approval vs. Advisory Committee Recommendation
    • 7.4.5. General Pricing Assumptions
    • 7.4.6. Individual Vaccine Assumptions
  • 7.5. Physicians and Specialists Included in this Study
    • 7.5.1. Interviews of Key Opinion Leaders (KOLs)
    • 7.5.2. Online Survey of High-Prescribing Physicians (non-KOLs)
  • 7.6. About the Authors
    • 7.6.1. Analyst
    • 7.6.2. Therapy Area Director
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Modes of HBV Transmission
  • Table 2: HBV Serological Markers and Test Interpretations
  • Table 3: Symptoms of HBV Infection
  • Table 4: HBV Vaccination Advisory Committees by Country
  • Table 5: HBV Immunization Recommendations by Country
  • Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
  • Table 7: Leading Vaccines for HBV, 2014
  • Table 8: Product Profile - Engerix-B
  • Table 9: Immunogenicity Profile - Engerix-B
  • Table 10: Safety Profile - Engerix-B
  • Table 11: Engerix-B SWOT Analysis, 2014
  • Table 12: Global Sales Forecasts ($m) for Engerix-B, 2012-2022
  • Table 13: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, by Country
  • Table 14: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, by Country
  • Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: HBV Structure and the Recombinant Vaccine Development Process
Back to Top